LeMaitre Vascular (LMAT) insider reports RSU, PSU vesting and share withholding

Rhea-AI Filing Summary

LeMaitre Vascular Inc disclosed insider equity transactions by its Senior V. P., Operations in December 2025. The officer acquired small amounts of common stock through the release of dividend equivalent rights on 12/11/2025 and 12/12/2025, with each right economically equivalent to one share of common stock.

On those dates, the issuer also withheld 90 shares on three separate occasions to satisfy tax withholding obligations tied to the vesting of restricted stock units and performance stock units originally granted in 2021 and 2022. After these transactions, the officer beneficially owned 4,417 shares of common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kamke Trent G

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR , INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior V. P., Operations

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/11/2025		M		11(1)	A	$0(1)	4,671	D
Common Stock	12/11/2025		F		90(2)	D	$83.36	4,581	D
Common Stock	12/12/2025		M		8(1)	A	$0(1)	4,589	D
Common Stock	12/12/2025		F		90(3)	D	$84	4,499	D
Common Stock	12/12/2025		M		8(1)	A	$0(1)	4,507	D
Common Stock	12/12/2025		F		90(4)	D	$84	4,417	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(5)	12/11/2025		M			11(5)	(5)	(5)	Common Stock	11	$0	0(6)	D
Dividend Equivalent Rights	(7)	12/12/2025		M			8(7)	(7)	(7)	Common Stock	8	$0	8.734	D
Dividend Equivalent Rights	(8)	12/12/2025		M			8(8)	(8)	(8)	Common Stock	8	$0	8.7256	D

Explanation of Responses:

1. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.

2. These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of restricted stock units awarded to the reporting person on 12/11/2021. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.

3. These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of restricted stock units awarded to the reporting person on 12/12/2022. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.

4. These shares represent shares withheld by the Issuer to satisfy tax withholding obligations incurred upon the vesting of performance stock units awarded to the reporting person on 12/12/2022. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.

5. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/11/2021. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

6. Fractional shares released (if any) on each vesting date were settled in cash, resulting in a final balance of zero.

7. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

8. These dividend equivalent rights were released in connection with the vesting of a performance stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did LeMaitre Vascular (LMAT) report in this Form 4?

The filing reports that the Senior V. P., Operations of LeMaitre Vascular Inc acquired common stock through the release of dividend equivalent rights and had shares withheld by the issuer to cover tax obligations related to vesting restricted stock units and performance stock units.

How many LeMaitre Vascular shares does the reporting person own after these transactions?

Following the reported transactions on 12/11/2025 and 12/12/2025, the Senior V. P., Operations beneficially owned 4,417 shares of LeMaitre Vascular common stock directly.

What are dividend equivalent rights mentioned in the LeMaitre Vascular (LMAT) filing?

The filing explains that each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and that shares reported in Table I were acquired upon the release of these rights on a one-for-one basis when related awards vested.

Why were some LeMaitre Vascular shares disposed of in this Form 4?

The filing states that certain shares were withheld by the issuer to satisfy tax withholding obligations that arose when restricted stock units and performance stock units granted in 2021 and 2022 vested. These withholding transactions are described as exempt sales under Rule 16b-3(e).

Which equity awards were involved in the LeMaitre Vascular insider transactions?

The transactions involved the vesting of restricted stock units granted on 12/11/2021, restricted stock units granted on 12/12/2022, and performance stock units granted on 12/12/2022, along with the associated dividend equivalent rights.

Were any derivative securities still held after the LeMaitre Vascular transactions?

The filing shows dividend equivalent rights as derivative securities. In one case, fractional shares released on vesting were settled in cash, resulting in a final balance of zero for that award, while other entries show remaining fractional balances noted in the table.